When Tablet Granulation Overrides Direct Compression: Potency and Friability Boundaries

Guanlian Powder Veterinary Grade API is typically routed into wet granulation rather than direct compression when the active load exceeds 40.0% w/w or when the API particle size distribution on the certificate of analysis shows a D50 below 100 μm, because flow-limited weight variation then exceeds USP <905> dosage-unit acceptance criteria. The granulation vehicle is purified water with 5.0% w/w povidone K30, added at 30–35°C under a peristaltic pump; the granulation step is performed in a Glatt GPCG 3 fluid-bed system with inlet air at 70°C, product temperature held at 38–42°C, and final moisture controlled to 1.8–2.2% w/w by loss-on-drying. Milling through a Quadro Comil U10 fitted with a 0.039 in grater screen at 2,000 rpm reduces oversized granules before lubrication. The extragranular phase is composed of microcrystalline cellulose PH102 at 28.0% w/w, crospovidone at 3.5% w/w, and sodium stearyl fumarate at 1.2% w/w; lubricant blending is limited to 4 min at 12 rpm in a 100 L bin blender to avoid excessive shear. Tabletting is run on a Korsch XL 400 rotary press at 45,000 tablets/hour using 9 mm round convex tooling, with pre-compression force at 4 kN and main compression force between 12 kN and 18 kN; ejection force is monitored below 2.0 kN to prevent scoring and capping. Friability is tested to Ph. Eur. 2.9.7 and remains below 1.0% w/w, while disintegration measured by USP <701> in purified water at 37.0°C is below 15 min. Terminal products are scored oral tablets for companion-animal dosing, typically administered to dogs in weight bands between 5 kg and 25 kg. Published data for this specific API in tablet form is limited; the formulation and process ranges align with the general monograph Ph. Eur. 0478 and current veterinary GMP expectations.

Sterile injectable processing of the veterinary-grade API as a solution requires the active concentration to remain below its solubility limit at the target fill volume; otherwise precipitation occurs during terminal sterilisation or long-term storage. The compounding vehicle is Water for Injection buffered to pH 5.5–6.0 with citrate or phosphate salts, and dissolved oxygen is reduced to ≤2.0 mg/L by nitrogen sparging before active addition. The bulk solution is clarified through a 0.45 μm polytetrafluoroethylene filter and then sterilized through two 0.22 μm polyethersulfone membranes arranged in series; filter integrity is tested by bubble point before and after filtration per 21 CFR 211.167. If the API demonstrates adequate stability at 121°C for 15 min, terminal steam sterilisation is used; otherwise aseptic filtration and isolator filling are required. For aseptic filling, Grade A conditions are maintained with settle plates at 0–1 CFU per exposure. Vials are 20 mL amber borosilicate glass with 10.5 mL fill volume and nitrogen headspace overlay. Sterility is verified by USP <71>, bacterial endotoxins by USP <85> with a limit not exceeding 0.25 EU/mg where the veterinary monograph requires, and visible particulates by USP <790>. Pre-filtration bioburden is controlled to ≤10 CFU/100 mL under 21 CFR 211.110. The terminal product is an injectable solution for cattle or swine, given by intramuscular or subcutaneous route. Published data for this specific configuration is limited; terminal sterilisation cycles must be validated with Geobacillus stearothermophilus spore challenges and bracketing studies according to the site’s sterilisation qualification protocol.

When the API is not sufficiently stable in aqueous solution across the proposed shelf life, sterile powder for injection is produced by lyophilization or aseptic crystallisation. The pre-lyophilization solution contains the API plus mannitol at 5.0% w/w as cryoprotectant and is sterilized through a 0.22 μm membrane. Lyophilization proceeds with primary drying at −35°C and secondary drying at 25°C for 8–12 h at 0.1 mbar; residual moisture is confirmed below 2.0% w/w by USP <921>. The dry sterile powder is filled into 10 mL or 20 mL tubular glass vials under Grade A laminar flow at 100–200 vials/min, then sealed with chlorobutyl rubber stoppers and aluminium caps. Container closure integrity is checked by dye ingress using 0.5% w/w methylene blue solution under −30 kPa vacuum for 10 min. Reconstitution immediately before administration uses Water for Injection to a final volume of 5.0 mL. The terminal product is a sterile dry injection powder for intramuscular or subcutaneous administration in food-producing or companion animals. Published data for this specific API configuration is limited; batch release includes USP <71>, USP <85>, and stability assignments under 21 CFR 211.166.

Capsule Fill Weight Segregation and Low-Dose Uniformity Across Animal Weight Bands

Encapsulation of the API for oral veterinary use is controlled by fill weight segregation when lactose monohydrate is the principal filler. A dry blend is acceptable only at active loading below 5.0% w/w and when the API-to-filler particle size ratio is less than 1:6; above these boundaries, wet granulation is performed to prevent fines migration through the hopper and tamping pins. Granulated material is dried to 2.0% w/w loss-on-drying, sized through a 0.8 mm oscillating granulator, and blended with 0.5% w/w colloidal silicon dioxide and 1.0% w/w magnesium stearate for 3 min. Capsule filling on a Bosch GKF 1500 operates at 60,000 capsules/hour with tare weight control and pin tamping adjustment; for a size 0 hard gelatin capsule, target fill weight is 250 mg with acceptance of ±5.0% by USP <905>. Empty capsules are conditioned at 23°C ± 2°C and 45% RH ± 5% RH for 24 h before filling to reduce brittleness. Post-fill metal detection is set at 1.0 mm ferrous and 1.5 mm non-ferrous thresholds. Dissolution testing follows USP <711> in 900 mL of pH 1.2 simulated gastric fluid at 50 rpm using apparatus II; where a compendial Q value exists, it controls release, and where no monograph exists, an immediate-release screening target of not less than 80% release in 30 min may be used during development only. The terminal product is a capsule for dogs or cats labelled by weight-band instructions for animals between 2 kg and 40 kg. Published data for this specific API in capsule form is limited; stability protocols are established under VICH GL 4 and Ph. Eur. 2.9.40 uniformity of dosage units.

Why Carrier Porosity Governs Blend Uniformity in Drinking-Water Powders?

Oral powder formulations for drinking-water administration require a water-soluble carrier such as lactose monohydrate, dextrose monohydrate, or sorbitol; carrier particle size is specified at D50 in the range 180–250 μm to reduce vibration-induced segregation during transport. Blend uniformity is measured by sampling 10 locations in a 300 L V-blender at 60% fill volume after 15 min mixing at 12 rpm; finished-product dose uniformity is tested to USP <905>, while in-process blend acceptance is product-specific. API loading in drinking-water powders is commonly 0.2–1.5% w/w, requiring geometric dilution in 3–5 steps through a 50 L drum tumbler to avoid agglomeration. Moisture protection is critical because the API gains weight above 60% RH; sachet packaging uses aluminium foil laminate with water vapour transmission rate below 0.5 g/m²/day at 38°C/90% RH per ASTM F1249-20. Reconstitution instructions require dissolution in 100 L to 1,000 L of drinking water within 2 min using propeller agitation at 300 rpm. The resulting solution or suspension is protected from light and used within 24 h because microbiological controls follow Ph. Eur. 5.1.4 category 3B limits. Terminal products are sachets or tubs for broiler, pig, or calf oral administration via drinker lines. Published data for this specific API in drinking-water powders is limited; field stability and water compatibility must be verified under VICH GL 5 and Regulation (EU) 2019/4 where applicable.

Granule production for oral veterinary administration differs from dry powder blending because the API is embedded within a pregelatinized starch or dextrin matrix to reduce dust generation and improve dose acceptance. In a high-shear mixer, the dry phase contains the API, pregelatinized starch at 35.0% w/w, microcrystalline cellulose at 20.0% w/w, and sodium starch glycolate at 3.0% w/w. Purified water is added at 18.0% w/w over 120 s through a peristaltic pump while impeller speed is held at 300 rpm and chopper speed at 1,500 rpm. The wet mass is extruded through a 0.8 mm screen and spheronized at 900 rpm for 3 min. Drying uses a fluid-bed dryer at inlet 60°C until moisture is 1.5–2.5% w/w; sieving retains granules between 250 μm and 850 μm per USP <786>. Fines below 125 μm are removed because they accelerate dissolution overshoot and reduce content uniformity. The granules are filled into single-dose sachets at 1.0 g or 2.0 g fill weights. Terminal product is an oral granule for direct administration or for mixing into a small portion of feed for swine or equine use. Published data for this specific API in granule form is limited; process acceptance criteria are aligned with Ph. Eur. 2.9.40 and the granule uniformity chapter of the relevant pharmacopoeia.

Carryover from Type A medicated premix is controlled by flush sequencing and density matching

Premix application of the API requires a Type A medicated article classification under 21 CFR 558.3 when incorporated into animal feed in the United States; in the European Union, comparable intermediate products must comply with Regulation (EU) 2019/4 and existing feed additive authorisations. Carrier selection is based on density compatibility with feed ingredients: calcium carbonate at bulk density 1.2–1.4 g/cm³, ground corn cobs at 0.35–0.45 g/cm³, or rice hulls at 0.40–0.50 g/cm³. A 100 kg double-ribbon mixer with 60% fill factor and 10 min mixing time is used for the first dilution. The API is pre-blended with 5.0 kg of carrier by geometric dilution before the remaining carrier is added. Homogeneity is sampled at 10 points and quantified by HPLC; acceptance is product-specific and established in the Type A medicated article approval, with mixer efficiency and cleanout validated under 21 CFR 225.65. Final premix concentration is commonly 1:100 to 1:1,000 of the active dose, requiring 1.0–10.0 kg of premix per tonne of complete feed. Carryover between batches is controlled by flush sequencing with 5.0 kg of salt or ground limestone after each run; residual API in the next batch is maintained below 0.1% w/w unless a validated worst-case carryover limit is established. Terminal product is a non-sterile premix for broiler, layer, or swine feed mills. Published data for this specific API in premix form may be limited; approval requires a safety file, residue depletion data, and MRL compliance under Regulation (EU) No 470/2009 where applicable.

Buffering capacity, not pH alone, determines preservative efficacy in multi-dose oral solutions

Oral solution manufacture with the veterinary-grade API begins with deionized water meeting purified water grade under USP <1231>; the active is dissolved at 25.0°C ± 2.0°C under nitrogen blanketing because oxidative degradation accelerates in solutions with dissolved oxygen above 4.0 mg/L. Buffer salts are selected to hold pH at 5.5–6.5; phosphate buffers are preferred over carbonate buffers because carbonate increases headspace pressure and can deform high-density polyethylene containers. Preservative loading depends on the octanol-water partition coefficient; a combination of methylparaben at 0.18% w/w and propylparaben at 0.02% w/w is acceptable only when justified by antimicrobial effectiveness testing under USP <51>. The final solution is filtered through a 100 μm polypropylene bag filter and filled into 250 mL, 500 mL, or 1 L high-density polyethylene bottles with induction-sealed liners. Fill volume is set to +2.0% of label claim at 20–25°C; amber polyethylene terephthalate bottles are used when photostability data show degradation under 1.2 million lux hours visible light and 200 W·h/m² near-ultraviolet per ICH Q1B. Terminal product is an oral solution for poultry, pigs, or calves, administered through drinking water or oral drench. Published data for this specific API in oral solutions is limited; stability assignment follows VICH GL 5 and microbiological limits follow Ph. Eur. 5.1.4 category 3B. A preservative-free alternative is feasible only for single-use containers where in-use period does not exceed 24 h.